PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $170,804 | -3.0% | 16,471 | +33.9% | 0.00% | 0.0% |
| Q2 2023 | $176,165 | +100.6% | 12,302 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $87,837 | -36.4% | 12,302 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $138,028 | +1.3% | 12,302 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $136,306 | +31.3% | 12,302 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $103,829 | -38.0% | 12,302 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $167,430 | +9.7% | 12,302 | +58.5% | 0.00% | 0.0% |
| Q4 2021 | $152,679 | -38.7% | 7,762 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $249,160 | -5.2% | 7,762 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $262,744 | +37.5% | 7,762 | +52.6% | 0.00% | 0.0% |
| Q1 2021 | $191,105 | +13.1% | 5,088 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $169,023 | -9.4% | 5,088 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $186,577 | +11.4% | 5,088 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $167,446 | +27.5% | 5,088 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $131,372 | – | 5,088 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |